Get the Stockscreener App
2.41
2.03%
-0.05
After Hours:
2.43
0.02
+0.83%
Nuvation Bio Inc stock is traded at $2.41, with a volume of 3.28M.
It is down -2.03% in the last 24 hours and up +23.59% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$2.46
Open:
$2.47
24h Volume:
3.28M
Relative Volume:
0.57
Market Cap:
$820.03M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-6.8857
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-5.86%
1M Performance:
+23.59%
6M Performance:
+0.42%
1Y Performance:
-32.68%
1-Day Range:
$2.35
$2.555
1-Week Range:
$2.35
$2.76
52-Week Range:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.41 | 837.05M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
What makes Nuvation Bio Inc. stock price move sharplyDaily Smart Money Movement Monitor Activated - metal.it
Nuvation Bio (NUVB.N) Surges 8.6% — Unpacking the Intraday Spike Without Fundamentals - AInvest
What institutional investors are buying Nuvation Bio Inc. stockStay informed with daily expert analysis - jammulinksnews.com
Is Nuvation Bio Inc. stock a growth or value playDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
How volatile is Nuvation Bio Inc. stock compared to the marketAchieve breakthrough performance with smart picks - jammulinksnews.com
What catalysts could drive Nuvation Bio Inc. stock higher in 2025Discover hidden gems in the stock market - jammulinksnews.com
Will Nuvation Bio Inc. stock benefit from interest rate changesEarly Buy Suggestion - metal.it
What drives Nuvation Bio Inc. stock priceSuperior stock growth - PrintWeekIndia
Published on: 2025-07-25 18:05:03 - PrintWeekIndia
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - BioSpace
Bullish Nuvation Bio Insiders Loaded Up On US$2.31m Of Stock - 富途牛牛
Is Nuvation Bio Inc. a good long term investmentFree Consultation - Autocar Professional
Nuvation Bio Inc. Stock Analysis and ForecastFree Stock Index Interpretation - Autocar Professional
What analysts say about Nuvation Bio Inc. stockTremendous gains - jammulinksnews.com
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma - TipRanks
Is Nuvation Bio Inc. stock a good hedge against inflationFree Investing Community - Newser
Why Nuvation Bio Inc. stock attracts strong analyst attentionLow Risk Entry Points - beatles.ru
Nuvation Bio's Mysterious 5% Surge: A Deep Dive into the Unseen Drivers - AInvest
How Nuvation Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - MSN
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):